Iloperidone: a new benzisoxazole atypical antipsychotic drug. Is it novel enough to impact the crowded atypical antipsychotic market?

被引：26

作者：

Albers, Lawrence James ^{[2
]}

Musenga, Alessandro ^{[1
]}

Raggi, Maria Augusta ^{[1
]}

机构：

[1] Univ Bologna, Dept Pharmaceut Sci, Lab Pharmacotoxicol Anal, I-40126 Bologna, Italy

[2] Univ Calif Irvine, Dept Psychiat, Long Beach, CA 90822 USA

来源：

EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2008年 / 17卷 / 01期

关键词：

atypical antipsychotic; iloperidone; pharmacodynamics; pharmacokinetics; schizophrenia treatment; therapeutic drug monitoring;

D O I：

10.1517/13543784.17.1.61

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Iloperidone is a new-generation atypical antipsychotic agent, acting as a serotonin/dopamine (5-HT2A/D-2) antagonist, under development by Vanda Pharmaceuticals for the treatment of schizophrenia, bipolar disorder and other psychiatric conditions. Chemically, iloperidone is a benzisoxazole, like risperidone, and shows a multiple receptor binding profile, sharing this feature with the other atypical antipsychotic agents. Administered orally, the drug is highly bound to plasma proteins and extensively metabolised. Several clinical trials have been carried out, to check efficacy, safety and side effects. in order to introduce iloperidone as an agent for the treatment of schizophrenia, a short overview of the disease and of the most important antipsychotic drugs available or under development will be reported. Iloperidone pharmacokinetics and pharmacodynamics are presented herein, together with an evaluation of clinical safety and efficacy results.

引用

页码：61 / 75

页数：15

共 77 条

[1] Pharmacotherapy of Schizophrenia: The Past, Present and Future [J].

Akhondzadeh, Shahin .

CURRENT DRUG THERAPY, 2006, 1 (01) :1-7

[2] Pharmacogenomic-guided rational therapeutic drug monitoring: Conceptual framework and application platforms for atypical antipsychotics [J].

Albers, LJ ;

Ozdemir, V .

CURRENT MEDICINAL CHEMISTRY, 2004, 11 (03) :297-312

[3] Side effects of atypical antipsychotic drugs [J].

Ananth, J ;

Parameswaran, S ;

Gunatilake, S .

CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (18) :2219-2229

[4] Central 5-HT2A and D-2 dopamine receptor occupancy after sublingual administration of ORG 5222 in healthy men [J].

Andree, B ;

Halldin, C ;

VrijmoeddeVries, M ;

Farde, L .

PSYCHOPHARMACOLOGY, 1997, 131 (04) :339-345

[5]

[Anonymous], PSYCHOPHARMACOLOGY A

[6] Putative antipsychotics with pronounced agonism at serotonin 5-HT1A and partial agonist activity at dopamine D2 receptors disrupt basal PPI of the startle reflex in rats [J].

Auclair, Agnes L. ;

Galinier, Alexandra ;

Besnard, Joel ;

Newman-Tancredi, Adrian ;

Depoortere, Ronan .

PSYCHOPHARMACOLOGY, 2007, 193 (01) :45-54

[7]

BAROLDI P, 2007, PHARMACOKINETIC PK P

[8] Iloperidone reduces sensorimotor gating deficits in pharmacological models, but not a developmental model, of disrupted prepulse inhibition in rats [J].

Barr, Alasdair M. ;

Powell, Susan B. ;

Markou, Athina ;

Geyer, Mark A. .

NEUROPHARMACOLOGY, 2006, 51 (03) :457-465

[9] Cost-effectiveness analysis of schizophrenia relapse prevention -: An economic evaluation of the ZEUS (Ziprasidone-Extended-Use-In-Schizophrenia) study in Spain [J].

Bernardo, Miguel ;

Azanza, Jose Ramon ;

Rubio-Terres, Carlos ;

Rejas, Javier .

CLINICAL DRUG INVESTIGATION, 2006, 26 (08) :447-457

[10] Muscarinic mechanisms of antipsychotic atypicality [J].

Bymaster, FP ;

Felder, CC ;

Tzavara, E ;

Nomikos, GG ;

Calligaro, DO ;

Mckinzie, DL .

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2003, 27 (07) :1125-1143

← 1 2 3 4 5 6 7 8 →